Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.
We have offices across 24 countries in Europe and North America, we export to over 50 countries worldwide and have six manufacturing sites. The Dechra Group employ over one thousand people and our revenue in 2018 reached £407.1m.
Our six Dechra Values: Dedication, Enjoyment, Courage, Honesty, Relationships and Ambition reflect the best aspects of behaviour and competence in Dechra. We embrace the values at every level of the business and everything about the business is underpinned by our values. How we talk to the people that matter, the way we always look to do things better and how we think of the people and the animals beyond the product.
We are active in Companion Animal, Equine and Food Producing Animal products.
Our key focus therapeutic areas are:
• Endocrinology
• Dermatology
• Anaesthesia and Analgesia
• Water Medication
• Diets and Nutrition
• Equine Locomotion
And we support our clients in practice with a wide range of materials and technical advice.
Follow us on Twitter - @Dechra
We have offices across 24 countries in Europe and North America, we export to over 50 countries worldwide and have six manufacturing sites. The Dechra Group employ over one thousand people and our revenue in 2018 reached £407.1m.
Our six Dechra Values: Dedication, Enjoyment, Courage, Honesty, Relationships and Ambition reflect the best aspects of behaviour and competence in Dechra. We embrace the values at every level of the business and everything about the business is underpinned by our values. How we talk to the people that matter, the way we always look to do things better and how we think of the people and the animals beyond the product.
We are active in Companion Animal, Equine and Food Producing Animal products.
Our key focus therapeutic areas are:
• Endocrinology
• Dermatology
• Anaesthesia and Analgesia
• Water Medication
• Diets and Nutrition
• Equine Locomotion
And we support our clients in practice with a wide range of materials and technical advice.
Follow us on Twitter - @Dechra
Location: United Kingdom, England, Northwich
Employees: 1001-5000
Founded date: 1997
Mentions in press and media 28
| Date | Title | Description |
| 20.08.2026 | Interim report January – June 2026 | Interim report January – June 2026 Thu, Aug 20, 2026 08:30 CET Report this content THE GROUP IN SUMMARY THE GROUP APRIL - JUNE JAN - JUNE FULL YEAR 2026 2025 2026 2025 2025 Net sales 6 239 7 012 9 613 11 586 20 087 Operating loss -20 579 -1... |
| 08.07.2026 | Takeovers aren’t the reason the London Stock Exchange is shrinking ‘Boards do not look for the exit’ | Takeovers like Schroders and Tate & Lyle grab the headlines but the far bigger problem for London is that there aren’t enough good companies arriving to replace them, says Henrik Persson There is a familiar account of London’s stock mar... |
| 18.06.2026 | The food system needs a rewiring, not a reinvention, Anterra Capital says after $100m raise | “The key in our space is not to focus on creating new categories but focus on the system itself and rewire it,” Anterra Capital founding partner Maarten Goossens said this week as his firm announced a $100 million first close of its Fund II... |
| 16.06.2026 | Anterra Capital Fuels Agri-Food Revolution with $100M AI, Biology Fund | Anterra Capital announced a $100 million first close for its third fund. This significant capital influx targets artificial intelligence and biological innovation across the $10 trillion global food and agriculture sector. The firm, managin... |
| 15.06.2026 | Anterra Capital: $100 Million First Close Of Fund III Targets AI And Biology Opportunities In Food And Agriculture | Anterra Capital announced the first close of its third fund at $100 million, with a target size of $200 million, as the specialist venture firm looks to capitalize on emerging opportunities created by artificial intelligence and biological ... |
| 02.06.2026 | - | Heartland Group Photo Muttville Senior Dog Rescue Photo Heartland Logo Muttville Logo Two organizations, Heartland Therapeutic Riding, Inc. and Muttville Senior Dog Rescue, were selected by the U.S. Giving Committee as this year's top recip... |
| 13.05.2026 | Interim report January – March 2026 | Interim report January – March 2026 Wed, May 13, 2026 08:30 CET Report this content The Group in summary 01/01/26 01/01/25 01/01/25 -31/03/26 -31/03/25 -31/12/25 Net sales 3 374 4 574 20 087 Operating result -22 228 -13 537 -83 501 Result a... |
| 15.01.2026 | Oxford Biomedica share prices jumps after takeover talks | Oxford Biomedica’s share price has rocketed in early morning trading after Swedish private equity firm EQT entered takeover talks for the gene and cell therapy group. Shares jumped 10.65 per cent to 889 pence, with shares rocketing 121.4 pe... |
| 05.11.2025 | Абу-Даби инвестировал £20 млрд в Великобританию | Первоначальное обязательство входило в рамки Суверенного инвестиционного партнерства, подписанного в 2021 году и реализуемого через инвестиционную компанию Mubadala Investment Co. и британское Управление по инвестициям (UK Office for Invest... |
| 13.10.2025 | Intervacc and Dechra extend distribution agreement for Intervacc’s equine strangles vaccine Strangvac by two years | Intervacc and Dechra extend distribution agreement for Intervacc’s equine strangles vaccine Strangvac by two years Mon, Oct 13, 2025 08:20 CET Report this content Intervacc AB (publ) announces today that the five-year distribution agreement... |
Show more